Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on ADC
Plus, news about Tris Pharma and ARS Pharmaceuticals: Merck KGaA’s lupus drug yields mixed data in mid-stage trial: The drugmaker’s TLR7/8 inhibitor, called enpatoran, missed one of two Phase 2 primary endpoints in a ...
Plus, news about Tris Pharma and ARS Pharmaceuticals:
Merck KGaA’s lupus drug yields mixed data in mid-stage trial: The drugmaker’s TLR7/8 inhibitor, called enpatoran, missed one of two Phase 2 primary endpoints in a ...
